CBD Reduced Involuntary Movements from Parkinson's Medication in Rats Without Reducing Its Benefits | Research

The takeaway

CBD significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease without impairing the motor benefits of the medication, working through CB1, PPARy, and endocannabinoid system pathways.

Movement disorder researchers, neurologists interested in cannabinoid therapeutics, Parkinson's disease clinicians.

CBD reduced L-DOPA dyskinesia in rats without impairing the medication's motor benefits

What the researchers found

CBD (30 mg/kg) and its fluorinated derivative PECS-101 (3 and 30 mg/kg) significantly reduced abnormal involuntary movements in L-DOPA-treated rats without reducing L-DOPA's motor benefits. CBD's antidyskinetic effects were blocked by CB1 and PPARy receptor antagonists and enhanced by TRPV-1 antagonism. CBD increased striatal anandamide and 2-AG concentrations and reduced neuroinflammation markers.

Why it matters

Dyskinesia affects up to 80% of Parkinson's patients on long-term L-DOPA therapy and is a major clinical problem. Finding a treatment that reduces dyskinesia without undermining L-DOPA's benefits would be a significant advance, and this preclinical evidence points to CBD as a candidate.

The numbers in context

CBD at 30 mg/kg; PECS-101 at 3 and 30 mg/kg; L-DOPA at 10 mg/kg for 3 weeks; CBD effects blocked by CB1 antagonist (1 mg/kg) and PPARy antagonist (4 mg/kg); enhanced by TRPV-1 antagonist capsazepine (5 mg/kg); significant increases in anandamide and 2-AG.

How the study worked

Unilateral 6-OHDA-lesioned rats were treated with L-DOPA for three weeks to induce dyskinesia, then received CBD or PECS-101 during the final two weeks. Abnormal involuntary movements were scored, and receptor antagonist studies identified mechanisms. Striatal endocannabinoid levels and inflammation markers were measured.

What this study cannot tell us

Animal model findings may not translate directly to humans. The 6-OHDA lesion model does not fully replicate the progressive nature of human Parkinson's disease. Only tested acute/subchronic CBD administration; long-term effects are unknown. Doses may not correspond to human-equivalent doses.

How to read the evidence

Preliminary: Preclinical animal study with detailed mechanistic analysis, but results require human validation before clinical conclusions can be drawn.

When this study was published

Published in 2025.

The bigger picture

This study adds to growing evidence that cannabinoids may help manage movement disorders. The identification of multiple receptor pathways (CB1, PPARy, TRPV-1) involved in CBD's antidyskinetic effects could inform development of more targeted treatments for Parkinson's-related dyskinesia.

Questions still open

Would these results translate to human Parkinson's patients with dyskinesia? What is the optimal CBD dose and timing relative to L-DOPA administration? Could the fluorinated derivative PECS-101 offer advantages over CBD for clinical development?

Common questions

What is L-DOPA-induced dyskinesia?

L-DOPA is the primary medication for Parkinson's disease, but long-term use frequently causes involuntary, uncontrollable movements called dyskinesia. Up to 80% of patients develop this side effect, and current treatment options are limited.

How might CBD help with Parkinson's?

In this rat study, CBD reduced the involuntary movements caused by L-DOPA without reducing the medication's intended benefits. It did this by interacting with multiple receptor systems and reducing neuroinflammation, suggesting several potential therapeutic mechanisms.

Read the original research

Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.

Progress in neuro-psychopharmacology & biological psychiatry, 141, 111456

View on PubMed ↗Publisher’s paper ↗

Citation

Nascimento, Glauce Crivelaro; Bálico, Gabriela Gonçalves; de Mattos, Bianca Andretto; Dos-Santos-Pereira, Mauricio; Oliveira, Igor Gustavo Carvalho; Queiroz, Maria Eugênia Costa; do Carmo Heck, Lilian; Navegantes, Luiz Carlos; Guimarães, Francisco Silveira; Del-Bel, Elaine. (2025). Cannabidiol improves L-DOPA-induced dyskinesia and modulates neuroinflammation and the endocannabinoid, endovanilloid and nitrergic systems.. Progress in neuro-psychopharmacology & biological psychiatry, 141, 111456. https://doi.org/10.1016/j.pnpbp.2025.111456